Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: Synthetic GnRH agonist (decapeptide)

Triptorelin

Plain-language summaryIntrigue 55 / 100

Triptorelin (Trelstar) is a synthetic 10-amino-acid GnRH agonist used in long-acting depot form for prostate cancer, endometriosis, and precocious puberty. The pharmacology has a counterintuitive twist: continuous (rather than the normal pulsatile) GnRH receptor stimulation initially causes a flare in testosterone or estrogen, then desensitizes and downregulates the receptor over one to two weeks, producing sustained suppression. So a drug that activates the GnRH system ends up shutting down sex hormone production. The depot formulations release peptide over one, three, or six months. In bodybuilding circles a single-shot dose has been used (anecdotally and unwisely) as post-cycle therapy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Mature FDA-approved GnRH agonist with solid evidence but negligible novelty in a crowded class

Look, triptorelin is a competent, well-characterized clinical tool that does exactly what it says it does. The pharmacology here is about as settled as pharmacology gets: flood the pituitary GnRH receptors continuously, desensitize and downregulate them, and you get medical castration. That mechanism was worked out decades before the 2000 FDA approval of Trelstar, and theres nothing particularly surprising left to find in it. This is not a criticism of the compound as a drug. It’s a criticism of the compound as a research frontier.

The GnRH agonist class is genuinely crowded. Leuprolide has dominated the space since the 1980s and remains the reference standard in most academic endocrine pharmacology labs. Goserelin and histrelin fill the same niche. Triptorelin competes on depot formulation options and a slightly differentiated approval profile, but it isnt best-in-class on any dimension that would give a bench scientist a reason to reach for it specifically over its peers. If your question requires a GnRH agonist probe, you probably already have a protocol built around leuprolide.

What we do credit: the evidence base is real. Multiple phase 3 RCTs across prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. Well-replicated mechanism, clean PK data across depot formulations (1-month, 3-month, 6-month), and a regulatory record that spans more than two decades. The translational signal is unambiguous. This is a compound that works in humans on its stated targets. Thats worth something, even if it doesn’t generate novel research questions.

Honestly, the scenario where triptorelin earns a slot in a serious research program is fairly narrow: HPG axis suppression as a model condition for studying downstream hormone-dependent biology, testosterone flare characterization in oncology models, or comparative GnRH receptor desensitization kinetics. For those questions, its a legitimate tool. But for investigators looking for compounds that open new mechanistic territory or generate the kind of data that moves a field, triptorelin doesnt offer that. The interesting GnRH biology is increasingly happening in the GnRH antagonist space (degarelix, relugolix) and in the kisspeptin-neurokinin signaling layer upstream of the receptor. Triptorelin sits downstream of that action and well behind the frontier.

We keep it in the library as a reference-grade GnRH agonist with documented PK and a clean regulatory trail. What we don’t think is that a researcher picking this up today is likely to find something new. The territory has been mapped.

Novelty

20

Mechanism promise

28

In-category differentiation

25

Evidence quality

78

Translational signal

72

Research bench value

42

Rationale Triptorelin’s high evidence and translational scores reflect genuine regulatory validation and well-replicated clinical outcomes across four approved indications, but those gains are largely cancelled by rock-bottom novelty (1970s chemistry, mechanism textbook-complete) and weak differentiation in a class that includes leuprolide, goserelin, and histrelin. Bench value exists but is constrained by the availability of interchangeable GnRH agonist reference tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic GnRH agonist (decapeptide)

A synthetic GnRH agonist decapeptide used for paradoxical HPG suppression in prostate cancer, endometriosis, and precocious puberty.

Abstract

Triptorelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; CAS 57773-63-4; molecular formula C64H82N18O13; molecular weight 1311.45) is a synthetic GnRH (LHRH) agonist decapeptide developed in the 1970s and approved by the FDA in 2000 (Trelstar). Mechanism: continuous occupation of pituitary GnRH receptors initially produces a flare in LH, FSH, and consequent sex hormone secretion (1 to 2 weeks); chronic exposure desensitizes and downregulates GnRH receptors, producing a sustained reduction in LH and FSH and, downstream, in testosterone (men) and estradiol (women). Plasma half-life of the parent peptide is approximately 3 hours; depot formulations release peptide over 1, 3, or 6 months for sustained suppression. Approved indications include locally advanced and metastatic prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. The flare period in prostate cancer is mitigated by concurrent androgen receptor antagonist (bicalutamide). Used as a reference GnRH agonist in academic endocrine pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-282Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Goserelin

Plain-language summaryIntrigue 50 / 100

Goserelin (Zoladex) is another GnRH agonist, distinguished from leuprolide and triptorelin not by mechanism (which is identical) but by formulation: a small biodegradable polymer rod implanted under the skin that releases the peptide gradually over 28 days or 12 weeks. Approved in 1989, used for prostate cancer, breast cancer (in premenopausal women), and endometriosis. The implant approach avoids the need for repeated intramuscular injections at the cost of a minor in-clinic procedure to insert the depot. Side effects mirror the broader GnRH agonist class: hot flashes, sexual dysfunction, bone loss, and mood effects from sex-hormone deprivation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

Clinically proven GnRH agonist depot implant with little remaining research frontier value

Look, goserelin is a genuine workhorse in hormone-sensitive oncology and gynecology. FDA approved since 1989, decades of clinical validation, well-characterized mechanism across multiple indications. This isnt a compound that failed to deliver. The problem, from a research standpoint, is that it has already delivered. Fully. There is very little left to discover here.

The mechanism is GnRH agonist desensitization: initial surge of LH and FSH followed by pituitary downregulation that drives testosterone and estrogen to castrate levels. This works exactly as described and has been working the same way since the 1980s. What we don’t like is that this mechanism is shared identically with leuprolide and triptorelin. There’s no pharmacological distinction between the three at the receptor level. What goserelin offers is a formulation story: the subcutaneous biodegradable polymer implant (Zoladex) delivers steady-state peptide release over 28-day or 12-week cycles, which is a real compliance advantage in clinical practice. But formulation engineering, while relevant to clinical pharmacology, isnt a research frontier in 2025.

Here’s the thing about the GnRH agonist class right now: the newer GnRH antagonists have largely moved the interesting questions forward. Degarelix and relugolix avoid the testosterone flare problem entirely, have faster pharmacodynamic offset, and relugolix’s oral bioavailability story is genuinely more interesting from a mechanistic standpoint. If you’re building a program around HPG-axis modulation, the research conversation is happening around antagonists, combinatorial approaches with AR pathway inhibitors, and neuroendocrine feedback dynamics, not revisiting agonist depot pharmacokinetics.

The evidence base here is solid, almost too solid. This is a decades-approved drug with a closed and thoroughly explored literature. That’s ideal for clinical practice and actively unhelpful for research opportunity. There’s minimal signal that goserelin as a probe or intervention object will generate publishable insights that don’t already exist. The one narrow angle where we’d consider it worth attention is as a reference standard in combination studies: comparing agonist versus antagonist flare dynamics, sequencing with enzalutamide or abiraterone, or fertility-preservation studies where precise suppression kinetics matter specifically to the depot format. But thats a specialized corner of an already mature field.

We’d characterize goserelin as indispensable to clinical practice and minimally interesting as a primary research object. The score reflects that the axes that matter most to a bench investigator, novelty, mechanism distinctiveness, and differentiation from alternatives, are all at floor. It earns points for being a real drug with real outcomes, but that’s not what the library is for.

Novelty

18

Mechanism promise

22

In-category differentiation

20

Evidence quality

78

Translational signal

80

Research bench value

35

Rationale Goserelin scores high on evidence quality and translational signal as a 35-year-old approved drug but scores very low on novelty, mechanism promise, and differentiation because its receptor-level pharmacology is identical to leuprolide and triptorelin, and newer GnRH antagonists have shifted the research conversation. The only distinguishing feature is the depot implant formulation, which is a clinical engineering story rather than a research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic GnRH agonist (decapeptide)

A synthetic GnRH agonist provided as a subcutaneous depot implant; approved for prostate cancer, breast cancer, and endometriosis.

Abstract

Goserelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-(1,1-dimethylethyl)-D-seryl-L-leucyl-L-arginyl-2-(carbamoylimino)hydrazinyl-L-prolinamide; CAS 65807-02-5; molecular formula C59H84N18O14; molecular weight 1269.41) is a synthetic GnRH agonist decapeptide developed at ICI (now AstraZeneca) and approved by the FDA in 1989 under the trade name Zoladex. Distinguished within the GnRH agonist class by formulation: subcutaneous biodegradable polymer implant rod releasing peptide over 28 days (3.6 mg) or 12 weeks (10.8 mg). Mechanism is identical to leuprolide and triptorelin. Approved for advanced prostate cancer, advanced breast cancer in pre- and perimenopausal women, endometriosis, and uterine leiomyomata. The implant delivery is preferred in some clinical settings for compliance and steady plasma profile. Used as a reference GnRH agonist with depot implant delivery.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-284Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.